Welcome to our dedicated page for Enlivex SEC filings (Ticker: ENLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enlivex Ltd.’s SEC filings document its status as an Israeli foreign private issuer with ordinary shares listed under ENLV, its clinical-stage Allocetra™ program, and its prediction markets treasury strategy centered on the RAIN token and Rain protocol.
Recent Form 6-K reports furnish current disclosures on regulatory clearances for Allocetra™ in age-related knee osteoarthritis, annual financial results, tokenized representations of the company’s ordinary shares, Rain protocol ecosystem updates, senior secured convertible debt, and the completed corporate name change from Enlivex Therapeutics Ltd. to Enlivex Ltd. The filings also reference registration statements and governance records tied to shareholder approvals and capital structure.
Enlivex Ltd. director Hart Gili filed an initial ownership report showing existing equity and option positions, with no new buy or sell transactions reported. The filing lists direct ownership of 7,672 ordinary shares and two option grants over 66,489 and 3,382 underlying ordinary shares. One option has a strike price of $2.69 and expires on December 31, 2033, and another has a strike price of $5.34 and expires on November 17, 2032. A footnote states that one option grant vests in equal annual installments over four years beginning on November 17, 2023.
Enlivex Ltd. director Shai A. Novik filed an initial Form 3 reporting his beneficial ownership. He holds 6,974,017 Ordinary Shares, par value NIS 0.40 per share, directly. The filing also lists multiple option awards to buy additional ordinary shares at exercise prices between 2.6900 and 12.2300, with expirations from 2030-05-03 to 2033-12-31. This Form 3 records existing holdings and does not show new purchases or sales.
Enlivex Ltd. director Roger Pomerantz filed an initial ownership report showing his current equity position. He holds options to acquire 150,000 ordinary shares at an exercise price of $5.967 per share, vesting annually over four years beginning on November 17, 2023, and directly owns 2,480 ordinary shares.
Enlivex Ltd. director Havron Avraham filed an initial ownership report showing a direct stake in ordinary shares and stock options. He holds 183,836 ordinary shares and options over 53,192 shares at an exercise price of $2.69 expiring on December 31, 2033, plus options over 3,382 shares at $5.34 expiring on November 17, 2032. The latter option grant vests in equal annual installments over four years beginning November 17, 2023.
Enlivex Ltd. Chief Medical Officer Einat Galamidi filed an initial ownership report showing her equity stake in the company. She holds 156,304 Ordinary Shares, par value NIS 0.40 per share, directly. She also holds employee stock options over 25,000 shares at an exercise price of $5.3400 per share expiring on March 29, 2032, and options over 10,000 shares at $3.2100 per share expiring on February 15, 2034. The filing does not show any new purchases or sales, only current holdings.
Enlivex Therapeutics Ltd. has formally changed its corporate name to Enlivex Ltd. following shareholder approval at an Extraordinary General Meeting held on February 3, 2026. Shareholders authorized the new name or another name containing the word “Enlivex,” subject to approval by the Israeli Registrar of Companies.
On February 10, 2026, the Registrar of Companies in Israel issued a Certificate of Change of Name, confirming the change to Enlivex Ltd. This certificate is attached as Exhibit 99.1 and the updated name is now incorporated by reference into the company’s existing U.S. registration statements on Forms S-8 and F-3.
Enlivex Therapeutics reported that its primary treasury asset, the RAIN token, has been listed on the Kraken cryptocurrency exchange effective February 9, 2026. Kraken is described as the second-largest U.S.-based crypto exchange, serving 5.7 million users with more than $2 trillion in 2025 trading volume.
The company believes this additional listing should expand access to RAIN and support greater secondary-market liquidity, price discovery, and accessibility for participants in the RAIN ecosystem. RAIN is the governance and utility token of a decentralized predictions and options protocol on the Arbitrum network, while Enlivex continues late-stage clinical development of its Allocetra™ therapy for osteoarthritis.
Enlivex Therapeutics Ltd. reports that shareholders at a February 3, 2026 Extraordinary General Meeting approved all proposals described in its prior notice and proxy materials, including amendments to the Company’s Articles of Association. The updated Articles, now in effect, govern share capital, meetings, board structure, and officer protections.
The Articles provide for a classified board starting with the annual meeting anticipated in 2026, where directors are elected for three-year, staggered terms, and allow issuance of redeemable securities subject to shareholder approval. They also permit reasonable corporate donations and include provisions for advance release, insurance, and indemnification of office holders, all subject to Israeli companies and securities laws.
Enlivex Therapeutics reported that its primary digital treasury asset, the RAIN token, has been listed on the WhiteBIT cryptocurrency exchange effective January 21, 2026. WhiteBIT is described as the largest European cryptocurrency exchange by traffic and part of W Group, serving more than 35 million customers globally.
The company expects RAIN trading on WhiteBIT to expand market access and enhance secondary market liquidity for the token, supporting its digital asset treasury strategy centered on RAIN. Enlivex remains a clinical-stage macrophage reprogramming immunotherapy company focused on late-stage development of Allocetra for osteoarthritis, while also positioning RAIN as its primary treasury reserve asset to give investors exposure to this digital token.
Enlivex Therapeutics plans to have its shares trade exclusively on the Nasdaq Capital Market and is voluntarily delisting its ordinary shares from the Tel Aviv Stock Exchange. In line with Israeli law and TASE rules, the last trading day in Tel Aviv is expected to be April 23, 2026, with delisting around April 26, 2026.
The company’s ordinary shares will continue to trade on Nasdaq under the symbol ENLV, and Enlivex will keep filing public reports with the SEC and Nasdaq. The board approved the move to operate under a single listing regime, reduce duplicative administrative costs, potentially concentrate liquidity on Nasdaq, and focus investor and public relations efforts on the U.S. capital markets.